Illumina (NASDAQ:ILMN) Updates FY25 Earnings Guidance

Illumina (NASDAQ:ILMN) issued an update on its FY25 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $4.50 for the period, compared to the consensus estimate of $4.51. Illumina also updated its FY 2025 guidance to 4.500-4.500 EPS.

Illumina Stock Down 0.8 %

NASDAQ:ILMN opened at $85.97 on Tuesday. Illumina has a 1 year low of $80.18 and a 1 year high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a market cap of $13.62 billion, a price-to-earnings ratio of -11.19, a PEG ratio of 1.60 and a beta of 1.17. The stock has a 50-day moving average price of $117.43 and a two-hundred day moving average price of $131.17.

Illumina (NASDAQ:ILMN) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts expect that Illumina will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ILMN. Guggenheim dropped their target price on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Citigroup dropped their price objective on Illumina from $130.00 to $90.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Barclays lowered Illumina from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $130.00 to $100.00 in a research note on Monday, February 10th. Royal Bank of Canada dropped their price objective on Illumina from $250.00 to $247.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Finally, TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and dropped their price objective for the company from $177.00 to $140.00 in a research note on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $149.25.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.